Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed

This article was originally published in PharmAsia News

Executive Summary

SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18

You may also be interested in...



Chinese Investor Consortium Buys SciClone But Relisting Possible

Against a background of positive changes to regulations and policies on pharmaceutical marketing in China, US-based SciClone has accepted a buyout offer from a consortium of Chinese investors, but may relist in China in the future.

Chi-Med’s Sinopharm Deal Opens Doors To China Market For Partners, CEO Says

The joint venture allows the newly formed subsidiary Hutchison Sinopharm to sell pharmaceuticals all over China and become a “super partner” for multinationals selling medicines in the country.

SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 2 of 2)

On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.

Related Content

UsernamePublicRestriction

Register

SC077701

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel